title: Role of proteomics to differentiate between benign and potentially malignant pancreatic cysts.
abstract: Pancreatic cystic neoplasms represent 10-15% of primary cystic masses of the pancreas. While pancreatic cysts are detected with an increasing frequency due to the use of advanced imaging modalities in clinical practice, the diagnosis of pancreatic cystic neoplasms remains unsatisfactory because available diagnostic techniques proved not sensitive enough so far. This study was designed to characterize the proteomic pattern of pancreatic cyst fluids obtained from various cystic lesions. Cyst fluids were collected by direct puncture during open surgery to avoid any possible contamination from other tissues. CEA, CA-19-9, and amylase concentrations were measured using specific immunoassays. After immunodepletion and fractionation by SDS-PAGE, proteins were digested and analyzed by LC-MS/MS. Specific histological lesions were found to be associated with distinct protein patterns. Interestingly, some of these proteins have been proposed as biomarkers of pancreatic cancer. Immunoblots allowed for verifying the differential expression in specific cyst fluids of two selected proteins, olfactomedin-4 and mucin-18. Finally, immunohistochemistry was performed to correlate these data with the expression pattern of olfactomedin-4 and mucin-18 in pancreatic cyst tissues. Results from this study indicate that proteomic analysis of cyst fluid could provide reliable candidates for developing new biomarkers for the preoperative management of malignant and premalignant pancreatic cysts.
authors.affiliation: Biomedical Proteomics Research Group, Department of Bioinformatics and Structural Biology, Faculty of Medicine, Geneva University, Geneva, Switzerland.
authors.forename: Aurora
authors.initials: A
authors.lastname: Cuoghi
authors.forename: Annarita
authors.initials: A
authors.lastname: Farina
authors.forename: Kaspar
authors.initials: K
authors.lastname: Z'graggen
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Dumonceau
authors.forename: Aldo
authors.initials: A
authors.lastname: Tomasi
authors.forename: Denis F
authors.initials: DF
authors.lastname: Hochstrasser
authors.forename: Muriel
authors.initials: M
authors.lastname: Genevay
authors.forename: Pierre
authors.initials: P
authors.lastname: Lescuyer
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Frossard
mesh_terms: D000681:Amylases / Q000032:analysis; D014408:Biomarkers, Tumor / Q000032:analysis*; D018395:CA-19-9 Antigen / Q000032:analysis; D002272:Carcinoembryonic Antigen / Q000032:analysis; D002853:Chromatography, Liquid; D020420:Cyst Fluid / Q000737:chemistry*; D004591:Electrophoresis, Polyacrylamide Gel; D016179:Granulocyte Colony-Stimulating Factor / Q000378:metabolism; D006801:Humans; D007118:Immunoassay; D015151:Immunoblotting; D007150:Immunohistochemistry; D009077:Mucins / Q000378:metabolism; D010181:Pancreatic Cyst / Q000175:diagnosis* / Q000378:metabolism; D010190:Pancreatic Neoplasms / Q000175:diagnosis* / Q000378:metabolism; D040901:Proteomics / Q000379:methods*; D053719:Tandem Mass Spectrometry
chemical_list: D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen; D009077:Mucins; C454127:OLFM4 protein, human; D016179:Granulocyte Colony-Stimulating Factor; D000681:Amylases